Washington Trust Advisors Inc. reduced its stake in Insulet Co. (NASDAQ:PODD – Get Rating) by 61.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 101 shares of the medical instruments supplier’s stock after selling 159 shares during the quarter. Washington Trust Advisors Inc.’s holdings […]
Insulet (NASDAQ:PODD – Get Rating) had its price objective boosted by Piper Sandler from $340.00 to $360.00 in a report issued on Friday, The Fly reports. Other equities research analysts have also issued reports about the stock. Wolfe Research started coverage on shares of Insulet in a report on Thursday, January 26th. They set a […]
Insulet (NASDAQ:PODD – Get Rating) had its target price upped by Robert W. Baird from $350.00 to $370.00 in a report published on Friday morning, The Fly reports. A number of other analysts have also recently commented on PODD. Stifel Nicolaus upped their price objective on Insulet from $300.00 to $342.00 and gave the company […]
Insulet (NASDAQ:PODD – Get Rating) had its price objective increased by equities researchers at UBS Group from $328.00 to $360.00 in a research note issued on Friday, The Fly reports. UBS Group’s target price would indicate a potential upside of 9.50% from the stock’s previous close. Several other analysts also recently weighed in on the […]
Insulet (NASDAQ:PODD – Get Rating) released its quarterly earnings results on Thursday. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.14, Briefing.com reports. The company had revenue of $358.10 million during the quarter, compared to the consensus estimate of $330.21 million. Insulet had […]